TO THE EDITOR: I read with interest the recent article by Tuttle et al.(1). For years, patients
have been prepared for 131I administration after thyroid cancer surgery. It is believed that …

TO THE EDITOR: I read with interest the careful experimental study by Postgård et al.(1) and
the accompanying editorial (2) in the Journal. This in vitro study suggested that thyroid …

TO THE EDITOR: With considerable interest we have read the recent report by Van
Nostrand et al. in which the authors compared the proportion of patients with positive scans …

TO THE EDITOR: Dorn et al. have described a dosimetryguided approach for calculating the
largest “safe” dose of 131I for treatment of differentiated thyroid cancer (1). With this method …

TO THE EDITOR: I would like to comment on the article by Coover et al.(1) on a simplified
method to comply with federal regulations 10CFR35. 75 during outpatient treatment with …

TO THE EDITOR: In a recent paper (1), Ma et al. considered explanations for the occasional
discordant findings between serum thyroglobulin and 131I whole-body scanning. They listed …

TO THE EDITOR: In regard to the prolonged measurements and frequent data sampling
performed after both diagnostic and therapeutic administration of radioiodine in thyroid …

TO THE EDITOR: Thyroid cancer is a rare malignancy (1). Most cases are of well-
differentiated epithelial papillary and follicular carcinomas. As most thyroid cancer has a low …

RESULTS Figure 1 illustrates the treatment and outcome of the patients in a flow diagram.
Forty-four patients were treated to ablate cervical residual functional thyroid tissue. Of these …

TO THE EDITOR: We read with interest the article by Yeung et al.(1) on therapeutic
radioiodine uptake in thyroid remnants after tracer dosimetry. The authors reported …